Discovery and mechanism studies of a novel ATG4B inhibitor Ebselen by drug repurposing and its anti-colorectal cancer effects in mice.

Discovery and mechanism studies of a novel ATG4B inhibitor Ebselen by drug repurposing and its anti-colorectal cancer effects in mice.
复制标题

DOI:
10.1186/s13578-022-00944-x
复制
发表时间:
2022-12-21
影响因子:
7.5
通讯作者:
Li, Min
Li, Min
中科院分区:
生物学2区
文献类型:
--
作者:
Xie, Huazhong;Qiang, Pengfei;Wang, Yao;Xia, Fan;Liu, Peiqing;Li, Min

文献摘要

参考文献

相似文献

Cysteine protease ATG4B, a key autophagy protein, is an attractive target for colorectal cancer therapy. However, ATG4B inhibitors with higher efficiency, safety, and clear mechanism are still limited. In this study, we discovered ATG4B inhibitors based on the FDA-approved drug library through FRET-based high-throughput screening and gel-based analysis. Among the nine hits, compound Ebselen showed the most potent ATG4B inhibitory activity (IC50 = 189 nM) and exhibited controllable selectivity and structural optimizable possibility against ATG4A and caspases. We then performed mass spectrometry assay and cysteine mutations to confirm that Ebselen could covalently bind to ATG4B at Cys74. Moreover, Cys292 and Cys361 instead of Cys74 are responsible for the redox-oligomerization and efficient activity inhibition of ATG4B. Ultimately through cell culture and mouse xenograft tumor models, we established the impact of Ebselen on autophagy and tumor suppression via ATG4B inhibition other than apoptosis. These results suggest that old drug Ebselen as an ATG4B inhibitor through oxidative modification may be repurposed as a promising anti-colorectal cancer drug. The online version contains supplementary material available at 10.1186/s13578-022-00944-x. High-throughput screening of ATG4B inhibitors based on FDA-approved drug library Ebselen can covalently bind to ATG4B at Cys74 Ebselen can promote ATG4B oligomerization at Cys292 and Cys361 Ebselen suppresses the growth of colorectal cancer cells and xenograft tumors via ATG4B inhibition The online version contains supplementary material available at 10.1186/s13578-022-00944-x.
DOI: 10.1038/s41467-021-23313-7
发表时间: 2021-05-24
影响因子: 16.6
作者:
Amporndanai K;Meng X;Shang W;Jin Z;Rogers M;Zhao Y;Rao Z;Liu ZJ;Yang H;Zhang L;O'Neill PM;Samar Hasnain S
通讯作者: Samar Hasnain S
DOI: 10.1016/j.bmc.2013.03.075
发表时间: 2013-06-01
影响因子: 3.5
作者:
Liu, Dazhi;Tian, Zhen;Yang, Cheng
通讯作者: Yang, Cheng
DOI: 10.1016/j.ejmech.2016.07.073
发表时间: 2016-11-10
影响因子: 6.7
作者:
Cleenewerck, Matthias;Grootaert, Mandy O. J.;Van der Veken, Pieter
通讯作者: Van der Veken, Pieter
DOI: 10.18632/oncotarget.11408
发表时间: 2016-10-11
期刊: Oncotarget
影响因子: --
作者:
Bortnik S;Choutka C;Horlings HM;Leung S;Baker JH;Lebovitz C;Dragowska WH;Go NE;Bally MB;Minchinton AI;Gelmon KA;Gorski SM
通讯作者: Gorski SM
Caspase 3 介导的癌症放射治疗过程中肿瘤细胞增殖的刺激。
DOI: 10.1038/nm.2385
发表时间: 2011-07-03
期刊: Nature medicine
影响因子: 82.9
作者:
通讯作者: --